GRITSTONE BIOPHARMACEUTICALS UK LTD
Company number 12631333
- Company Overview for GRITSTONE BIOPHARMACEUTICALS UK LTD (12631333)
- Filing history for GRITSTONE BIOPHARMACEUTICALS UK LTD (12631333)
- People for GRITSTONE BIOPHARMACEUTICALS UK LTD (12631333)
- More for GRITSTONE BIOPHARMACEUTICALS UK LTD (12631333)
Date (document was filed at Companies House) | Type | Description (of the document filed at Companies House) | View / Download (PDF file, link opens in new window) |
---|---|---|---|
31 May 2024 | CS01 | Confirmation statement made on 28 May 2024 with no updates | |
13 Feb 2024 | AA | Accounts for a dormant company made up to 31 May 2023 | |
14 Jul 2023 | AP01 | Appointment of Vassiliki Economides as a director on 12 July 2023 | |
10 Jul 2023 | CS01 | Confirmation statement made on 28 May 2023 with no updates | |
25 Jan 2023 | AA | Accounts for a dormant company made up to 31 May 2022 | |
04 Oct 2022 | TM01 | Termination of appointment of Rahsaan Thompson as a director on 27 September 2022 | |
31 May 2022 | CS01 | Confirmation statement made on 28 May 2022 with no updates | |
02 Mar 2022 | AA | Accounts for a dormant company made up to 31 May 2021 | |
07 Jun 2021 | CS01 | Confirmation statement made on 28 May 2021 with updates | |
12 May 2021 | PSC05 | Change of details for Gritstone Oncology, Inc. as a person with significant control on 3 May 2021 | |
02 Feb 2021 | PSC02 | Notification of Gritstone Oncology, Inc. as a person with significant control on 29 May 2020 | |
02 Feb 2021 | PSC09 | Withdrawal of a person with significant control statement on 2 February 2021 | |
04 Jan 2021 | TM01 | Termination of appointment of Jean-Marc Bellemin as a director on 11 December 2020 | |
29 May 2020 | NEWINC |
Incorporation
Statement of capital on 2020-05-29
|